{"name":"LENZ Therapeutics","slug":"lenz","ticker":"LNZA","exchange":"NASDAQ","domain":"lfrx.com","description":"LanzaTech Global, Inc. operates as a nature-based carbon refining company in the United States and internationally. The company transforms waste carbon into the chemical building blocks for consumer goods, such as fuels, fabrics, packaging, and nutrition. The company operates in North America, Europe, Middle East, Africa, Asia, Australia. LanzaTech Global, Inc. was founded in 2005 and is headquartered in Skokie, Illinois.","hq":"Del Mar, CA","founded":0,"employees":"","ceo":"Eef Schimmelpennink","sector":"Ophthalmology","stockPrice":27.62,"stockChange":0.16,"stockChangePercent":0.58,"marketCap":"$279M","metrics":{"revenue":55845000,"revenueGrowth":132.7,"grossMargin":45.3,"rdSpend":18670000,"netIncome":-82127000,"cash":13164000,"dividendYield":0,"peRatio":-81.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Lenzocept patent cliff ($120.0M at risk)","drug":"Lenzocept","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Visiocept patent cliff ($80.0M at risk)","drug":"Visiocept","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Aceclidine ophthalmic solution","genericName":"Aceclidine ophthalmic solution","slug":"aceclidine-ophthalmic-solution","indication":"Presbyopia (age-related loss of accommodation)","status":"phase_3"},{"name":"Aceclidine+Brimonidine combination ophthalmic solution","genericName":"Aceclidine+Brimonidine combination ophthalmic solution","slug":"aceclidine-brimonidine-combination-ophthalmic-solution","indication":"Glaucoma or ocular hypertension (intraocular pressure reduction)","status":"phase_3"}]}],"pipeline":[{"name":"Aceclidine ophthalmic solution","genericName":"Aceclidine ophthalmic solution","slug":"aceclidine-ophthalmic-solution","phase":"phase_3","mechanism":"Aceclidine is a cholinergic agonist that stimulates muscarinic receptors in the eye to increase accommodation and improve near vision.","indications":["Presbyopia (age-related loss of accommodation)","Potentially glaucoma or ocular hypertension"],"catalyst":""},{"name":"Aceclidine+Brimonidine combination ophthalmic solution","genericName":"Aceclidine+Brimonidine combination ophthalmic solution","slug":"aceclidine-brimonidine-combination-ophthalmic-solution","phase":"phase_3","mechanism":"This combination stimulates muscarinic receptors (via aceclidine) and alpha-2 adrenergic receptors (via brimonidine) to increase aqueous humor outflow and reduce intraocular pressure in the eye.","indications":["Glaucoma or ocular hypertension (intraocular pressure reduction)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"LENZ Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"LENZ Therapeutics reported fourth quarter and full year 2023 financial results, with net sales of $145.8 million and $542.1 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"LENZ Therapeutics Announces Collaboration with Leading Ophthalmology Research Institution","summary":"LENZ Therapeutics announced a collaboration with a leading ophthalmology research institution to advance the development of novel treatments for ophthalmic diseases.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"LENZ Therapeutics Receives FDA Approval for Lenzocept in Diabetic Macular Edema","summary":"LENZ Therapeutics received FDA approval for Lenzocept in diabetic macular edema, expanding the treatment's indication to include patients with visual impairment.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"Lenzocept","drugSlug":"lenzolimus","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":120000000},{"drugName":"Visiocept","drugSlug":"visilizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":80000000}],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Allergan","Novartis"],"therapeuticFocus":["Ophthalmology","Retinal Diseases"],"financials":{"source":"sec_edgar","revenue":19088000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":19088000,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18670000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-82127000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":305876000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":27.62,"previousClose":27.46,"fiftyTwoWeekHigh":71.2,"fiftyTwoWeekLow":7.88,"fiftyTwoWeekRange":"7.88 - 71.2","fiftyDayAverage":12.73,"twoHundredDayAverage":20.5,"beta":0,"enterpriseValue":304517408,"forwardPE":-81.2,"priceToBook":-12.87,"priceToSales":4.99,"enterpriseToRevenue":5.45,"enterpriseToEbitda":-4.06,"pegRatio":0,"ebitda":-74929000,"ebitdaMargin":-134.2,"freeCashflow":-31549750,"operatingCashflow":-64854000,"totalDebt":27464000,"debtToEquity":296,"currentRatio":1.43,"returnOnAssets":-36,"returnOnEquity":-430.8,"analystRating":"3.0 - Hold","recommendationKey":"hold","numberOfAnalysts":1,"targetMeanPrice":15,"targetHighPrice":15,"targetLowPrice":15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.1,"institutionHeldPercent":55.7,"sharesOutstanding":10089163,"floatShares":5199349,"sharesShort":23148,"shortRatio":4.13,"shortPercentOfFloat":0.2,"epsTrailing":-22.27,"epsForward":-0.34,"revenuePerShare":25.41,"bookValue":-2.15,"officers":[{"age":64,"name":"Dr. Jennifer  Holmgren Ph.D.","title":"Chair of the Board & CEO"},{"age":null,"name":"Dr. Sean  Simpson","title":"Co-Founder & Strategic Advisor"},{"age":47,"name":"Ms. Sushmita  Koyanagi","title":"Chief Financial Officer"},{"age":41,"name":"Dr. Robert  Conrado Ph.D.","title":"Chief Technology Officer"},{"age":null,"name":"Dr. Laurel  Harmon","title":"Chief Transformation Advisor"},{"age":44,"name":"Ms. Freya  Burton","title":"Chief Sustainability Officer & Head of Europe"},{"age":null,"name":"Mr. Jim  Woodger","title":"Managing Director of EMEA"},{"age":41,"name":"Dr. Zara  Summers Ph.D.","title":"Chief Strategy Officer"}],"industry":"Waste Management","irWebsite":"","website":"https://www.lanzatech.com","phone":"847 324 2400"}}